At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 52 enrolled
Drug / intervention
MYK-491 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-blind, Placebo-controlled, Two-Part, Adaptive Design Study of Safety, Tolerability, Preliminary Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of MYK-491 in Patients With Stable Heart Failure With Reduced Ejection Fraction
In Brief
A Phase 2 clinical trial evaluating MYK-491 and Placebo for Heart Failure With Reduced Ejection Fraction and Dilated Cardiomyopathy. Completed, enrolled 52 participants across 17 sites in 7 countries.
Detailed Summary
The purpose of this Phase 1b/2a study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MYK-491 in patients with stable heart failure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFrance, Germany, Netherlands, Poland, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartFeb 2018
First PostedFeb 2018
Primary CompletionOct 2019
TodayJul 2026
First PostedFeb 27, 2018
Enrollment StartFeb 6, 2018
Primary CompletionOct 24, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.3 years ago
Interventions
MYK-491drug
Single Ascending Dose and Multiple Ascending Dose of MYK-491
Placebodrug
Single Ascending Dose and Multiple Ascending Dose of placebo